Prices for specialty drugs continue to rise at a pace that far exceeds inflation.
A new study from AARP and a research unit at the University of Minnesota found the average annual retail price for 101 commonly used specialty medications hit $52,486 in 2015, an increase of 9.6 percent compared with the previous year.
The average annual price of the drugs nearly tripled over a 10-year period, according to the report, which comes as employers and health plans are citing high-priced medications as a key driver in overall health care costs.
"I think it really drives home the importance of trying to find solutions to this problem," said Leigh Purvis with the AARP Public Policy Institute.
The trade group for pharmaceutical manufacturers disputed the report, saying the AARP methodology "cherry picks" the medicines that it includes under the label of specialty pharmaceuticals.
The report also ignores the impact of discounts and rebates that health plans and pharmaceutical benefit managers (PBMs) negotiate with drug companies to reduce the actual cost, said Holly Campbell, a spokeswoman with the Pharmaceutical Research and Manufacturers Association (PhRMA). She said recent reports from two large PBMs cited drug spending increases of less than 4 percent in 2016.
"AARP's report maintains the flawed methodology of earlier efforts which has been criticized for misrepresenting the dynamics of the competitive marketplace for medicines," Campbell said in a statement.
Specialty drugs as defined by the report include those administered by injection and medicines that exceed certain price thresholds. They often require special handling and storage, AARP said, and are used to treat conditions such as rheumatoid arthritis, multiple sclerosis and cancer.